Lucid Diagnostics (LUCD) Cash from Investing Activities Growth (1y) (2022 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -4,224.26% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 95.53% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 3.20% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -18.20% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -208.79% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -187.82% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -397.90% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -514.25% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -211.17% |
| 10 | Lucid Diagnostics | 145.00 Mn | 117.12 Mn | -325,000.00 | -131.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -131.18% |
| Dec 31, 2025 | 80.31% |
| Sep 30, 2025 | 92.00% |
| Mar 31, 2025 | -151.35% |
| Dec 31, 2024 | -48.00% |
| Sep 30, 2024 | -2,400.00% |
| Mar 31, 2024 | -117.65% |
| Dec 31, 2023 | 13.79% |
| Sep 30, 2023 | 98.94% |
| Jun 30, 2023 | 99.38% |
| Mar 31, 2023 | 88.51% |
| Dec 31, 2022 | 75.36% |
| Sep 30, 2022 | -4,617.86% |
| Jun 30, 2022 | -243,500.00% |
| Mar 31, 2022 | -1,544.44% |